Environmental

Low Direct Environmental Footprint: Genmab operates as a biotechnology company with limited manufacturing and a focus on R&D, resulting in a relatively low direct carbon footprint compared to peers in heavy manufacturing or large-scale pharma production.

Sustainability Initiatives: The company has formalized sustainability targets, including energy efficiency and waste reduction in its facilities, and reports progress in line with global standards such as the UN Global Compact.

Supply Chain Oversight: Genmab has implemented supplier codes of conduct and environmental screening for key partners, though full traceability and Scope 3 emissions reporting are still developing relative to best-in-class peers.

Genmab’s environmental risk profile is favorable due to its R&D-centric model and proactive sustainability policies. While supply chain transparency is improving, the company’s direct impact remains low and its environmental management is robust for its sector.

Social

Workforce Engagement and Diversity: Genmab demonstrates strong employee engagement, with above-average retention and a focus on diversity and inclusion, including gender diversity targets at management levels.

Product Safety and Patient Access: The company maintains rigorous clinical trial standards and pharmacovigilance, with no major safety controversies reported. It also partners to improve patient access to innovative therapies.

Community and Stakeholder Relations: Genmab invests in community outreach and STEM education, and maintains transparent stakeholder communications, though its scale limits the breadth of its social programs compared to larger peers.

Genmab’s social performance is strong, driven by a positive workplace culture, high standards for patient safety, and active stakeholder engagement. The company’s size constrains the reach of its social initiatives, but core practices are well above sector norms.

Governance

Experienced and Independent Board: Genmab’s board is majority independent, with deep industry expertise and a strong track record in biotech governance.

Robust Compliance and Risk Management: The company maintains comprehensive compliance programs, including anti-corruption, data privacy, and clinical ethics, with no material regulatory breaches reported.

Capital Discipline and Shareholder Alignment: Genmab exhibits prudent capital allocation, low leverage (debt/equity ratio 0.03), and moderate stock-based compensation (3.3% of revenue), supporting long-term shareholder interests.

Genmab’s governance is a clear strength, with an independent board, strong compliance culture, and disciplined capital management. These factors position the company well for sustainable growth and risk mitigation.

Overall Score

Genmab demonstrates strong ESG performance across all pillars. Its low environmental footprint, robust social practices, and best-in-class governance distinguish it among biotech peers. The company’s proactive risk management and stakeholder alignment support its long-term sustainability.